The global market for Investigational New Drug CDMO was estimated at US$11.3 Billion in 2024 and is projected to reach US$15.8 Billion by 2030, growing at a CAGR of 5.8% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Investigational New Drug CDMO market.
Another breakthrough in the industry is the use of artificial intelligence (AI) and machine learning (ML) in drug formulation and process optimization. AI-driven predictive modeling helps CDMOs identify the most effective drug formulations, optimize stability conditions, and enhance process efficiencies. Additionally, automation and robotics in laboratory and manufacturing environments have improved precision in compound handling, minimizing human errors and ensuring reproducibility in IND production. The adoption of single-use bioprocessing technologies is another trend gaining momentum, particularly in biologics and cell and gene therapy manufacturing. These disposable systems reduce contamination risks, lower operational costs, and enhance flexibility, making them ideal for early-stage clinical production.
Another significant trend is the globalization of IND CDMO services, with companies expanding their operations across North America, Europe, and Asia-Pacific. Emerging markets, particularly in China and India, are witnessing rapid growth in CDMO capabilities due to cost advantages, skilled workforce availability, and favorable government policies promoting pharmaceutical outsourcing. Additionally, the rising focus on regulatory compliance and quality assurance is influencing CDMOs to adopt Good Manufacturing Practice (GMP) guidelines and implement stringent quality control measures to meet the requirements of the FDA, EMA, and other global regulatory agencies.
A further notable trend is the growing emphasis on accelerated clinical development timelines. With the pharmaceutical industry prioritizing fast-track approvals for breakthrough therapies, CDMOs are enhancing their capabilities to support expedited IND submissions. This includes offering integrated drug development solutions that combine formulation, analytical testing, and clinical trial supply management under a single contract, reducing timelines and improving project efficiency. The increasing adoption of decentralized clinical trials (DCTs) is also influencing CDMOs to adapt their clinical supply chains to meet the demands of remote and hybrid trial models.
Another crucial factor propelling market growth is the rising adoption of biologics and cell and gene therapies. The surge in demand for advanced therapeutic modalities has created a need for CDMOs equipped with high-containment manufacturing facilities and expertise in viral vector production, mRNA technology, and regenerative medicine. Furthermore, the increase in orphan drug designations and expedited regulatory pathways, such as the FDA’s Fast Track and Breakthrough Therapy designations, are pushing pharmaceutical firms to seek agile and highly capable CDMO partners to speed up clinical development and regulatory approval processes.
The strategic shift toward virtual biotech models is also fueling demand for IND CDMO services. Many small and mid-sized biotech companies lack in-house manufacturing and regulatory capabilities, making outsourcing an essential strategy for advancing their drug candidates. Additionally, stringent regulatory requirements in early-phase clinical development are compelling pharmaceutical companies to collaborate with experienced CDMOs that offer regulatory consulting, risk mitigation strategies, and GMP-compliant production. Lastly, the growing trend of CDMO partnerships with big pharma to co-develop and manufacture investigational drugs is further driving market expansion, ensuring that innovative therapies reach clinical trials faster while maintaining high-quality standards.
Segments: Product (Small Molecule, Large Molecule); Service (Contract Development, Contract Manufacturing); End-Use (Pharmaceutical Companies, Biotech Companies, Others)
Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.
The analysts continuously track trade developments worldwide, drawing insights from leading global economists and over 200 industry and policy institutions, including think tanks, trade organizations, and national economic advisory bodies. This intelligence is integrated into forecasting models to provide timely, data-driven analysis of emerging risks and opportunities.
Investigational New Drug CDMO Market - Key Trends & Growth Drivers Summarized
The Contract Development and Manufacturing Organization (CDMO) market for Investigational New Drugs (INDs) has become a critical component in the pharmaceutical and biotechnology industries. As pharmaceutical companies continue to focus on innovation while outsourcing drug development and manufacturing, CDMOs play a vital role in accelerating the path from preclinical research to clinical trials. IND CDMOs specialize in offering end-to-end solutions, including formulation development, clinical trial material manufacturing, regulatory support, and analytical services, enabling pharmaceutical firms to navigate the complex drug approval process efficiently. Given the increasing complexity of drug molecules, stringent regulatory requirements, and growing demand for specialized expertise, the role of CDMOs in the IND market is expanding rapidly, shaping the future of drug development worldwide.How Are Technological Advancements Transforming IND CDMO Services?
The IND CDMO market is undergoing a significant transformation driven by technological innovations that enhance efficiency, compliance, and speed in drug development. One of the most important advancements is the integration of continuous manufacturing techniques, which streamline production processes, minimize waste, and improve product consistency. Unlike traditional batch manufacturing, continuous manufacturing allows for real-time quality monitoring, reducing the risk of variability and improving scalability for early-phase drug production.Another breakthrough in the industry is the use of artificial intelligence (AI) and machine learning (ML) in drug formulation and process optimization. AI-driven predictive modeling helps CDMOs identify the most effective drug formulations, optimize stability conditions, and enhance process efficiencies. Additionally, automation and robotics in laboratory and manufacturing environments have improved precision in compound handling, minimizing human errors and ensuring reproducibility in IND production. The adoption of single-use bioprocessing technologies is another trend gaining momentum, particularly in biologics and cell and gene therapy manufacturing. These disposable systems reduce contamination risks, lower operational costs, and enhance flexibility, making them ideal for early-stage clinical production.
What Market Trends Are Reshaping the IND CDMO Landscape?
The IND CDMO market is witnessing several key trends that are reshaping its growth trajectory. One of the most prominent trends is the increasing demand for specialized CDMO services in biologics and advanced therapies. With the rapid expansion of monoclonal antibodies, cell and gene therapies, and RNA-based drugs, pharmaceutical companies are seeking CDMOs with expertise in handling complex biologic formulations, requiring specialized infrastructure and regulatory knowledge. This shift is prompting many CDMOs to invest heavily in biopharmaceutical production capabilities, including high-containment facilities for viral vector and mRNA-based therapeutics.Another significant trend is the globalization of IND CDMO services, with companies expanding their operations across North America, Europe, and Asia-Pacific. Emerging markets, particularly in China and India, are witnessing rapid growth in CDMO capabilities due to cost advantages, skilled workforce availability, and favorable government policies promoting pharmaceutical outsourcing. Additionally, the rising focus on regulatory compliance and quality assurance is influencing CDMOs to adopt Good Manufacturing Practice (GMP) guidelines and implement stringent quality control measures to meet the requirements of the FDA, EMA, and other global regulatory agencies.
A further notable trend is the growing emphasis on accelerated clinical development timelines. With the pharmaceutical industry prioritizing fast-track approvals for breakthrough therapies, CDMOs are enhancing their capabilities to support expedited IND submissions. This includes offering integrated drug development solutions that combine formulation, analytical testing, and clinical trial supply management under a single contract, reducing timelines and improving project efficiency. The increasing adoption of decentralized clinical trials (DCTs) is also influencing CDMOs to adapt their clinical supply chains to meet the demands of remote and hybrid trial models.
What Is Driving the Growth of the IND CDMO Market?
The growth in the Investigational New Drug CDMO market is driven by several factors, including rising pharmaceutical R&D investments, increasing complexity of drug molecules, and the growing need for outsourcing among biopharmaceutical companies. A key driver is the expanding pipeline of novel therapeutics, particularly in oncology, neurology, and rare diseases. With many pharmaceutical firms focusing on precision medicine and targeted therapies, CDMOs are witnessing heightened demand for specialized formulation and analytical services tailored to complex drug candidates.Another crucial factor propelling market growth is the rising adoption of biologics and cell and gene therapies. The surge in demand for advanced therapeutic modalities has created a need for CDMOs equipped with high-containment manufacturing facilities and expertise in viral vector production, mRNA technology, and regenerative medicine. Furthermore, the increase in orphan drug designations and expedited regulatory pathways, such as the FDA’s Fast Track and Breakthrough Therapy designations, are pushing pharmaceutical firms to seek agile and highly capable CDMO partners to speed up clinical development and regulatory approval processes.
The strategic shift toward virtual biotech models is also fueling demand for IND CDMO services. Many small and mid-sized biotech companies lack in-house manufacturing and regulatory capabilities, making outsourcing an essential strategy for advancing their drug candidates. Additionally, stringent regulatory requirements in early-phase clinical development are compelling pharmaceutical companies to collaborate with experienced CDMOs that offer regulatory consulting, risk mitigation strategies, and GMP-compliant production. Lastly, the growing trend of CDMO partnerships with big pharma to co-develop and manufacture investigational drugs is further driving market expansion, ensuring that innovative therapies reach clinical trials faster while maintaining high-quality standards.
Report Scope
The report analyzes the Investigational New Drug CDMO market, presented in terms of market value (US$ Thousand). The analysis covers the key segments and geographic regions outlined below.Segments: Product (Small Molecule, Large Molecule); Service (Contract Development, Contract Manufacturing); End-Use (Pharmaceutical Companies, Biotech Companies, Others)
Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.
Key Insights:
- Market Growth: Understand the significant growth trajectory of the Small Molecule segment, which is expected to reach US$9.7 Billion by 2030 with a CAGR of a 4.7%. The Large Molecule segment is also set to grow at 7.6% CAGR over the analysis period.
- Regional Analysis: Gain insights into the U.S. market, estimated at $3.0 Billion in 2024, and China, forecasted to grow at an impressive 5.7% CAGR to reach $2.5 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.
Why You Should Buy This Report:
- Detailed Market Analysis: Access a thorough analysis of the Global Investigational New Drug CDMO Market, covering all major geographic regions and market segments.
- Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
- Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Investigational New Drug CDMO Market.
- Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.
Key Questions Answered:
- How is the Global Investigational New Drug CDMO Market expected to evolve by 2030?
- What are the main drivers and restraints affecting the market?
- Which market segments will grow the most over the forecast period?
- How will market shares for different regions and segments change by 2030?
- Who are the leading players in the market, and what are their prospects?
Report Features:
- Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
- In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
- Company Profiles: Coverage of players such as AGC Biologics, Aurigene Discovery, Bachem Holding AG, BioCina, Biocon and more.
- Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.
Select Competitors (Total 34 Featured):
- AGC Biologics
- Aurigene Discovery
- Bachem Holding AG
- BioCina
- Biocon
- Cambrex Corporation
- Catalent
- Emergent BioSolutions
- Fujifilm Diosynth
- Hovione
- Jubilant Pharmova
- Laurus Labs
- Lonza Group
- Recipharm AB
- Samsung Biologics
- Siegfried Holding AG
- Syngene International Ltd.
- Thermo Fisher Scientific
- WuXi AppTec
- WuXi Biologics
Tariff Impact Analysis: Key Insights for 2025
Global tariff negotiations across 180+ countries are reshaping supply chains, costs, and competitiveness. This report reflects the latest developments as of April 2025 and incorporates forward-looking insights into the market outlook.The analysts continuously track trade developments worldwide, drawing insights from leading global economists and over 200 industry and policy institutions, including think tanks, trade organizations, and national economic advisory bodies. This intelligence is integrated into forecasting models to provide timely, data-driven analysis of emerging risks and opportunities.
What’s Included in This Edition:
- Tariff-adjusted market forecasts by region and segment
- Analysis of cost and supply chain implications by sourcing and trade exposure
- Strategic insights into geographic shifts
Buyers receive a free July 2025 update with:
- Finalized tariff impacts and new trade agreement effects
- Updated projections reflecting global sourcing and cost shifts
- Expanded country-specific coverage across the industry
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERSIV. COMPETITION
1. MARKET OVERVIEW
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
III. MARKET ANALYSIS
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AGC Biologics
- Aurigene Discovery
- Bachem Holding AG
- BioCina
- Biocon
- Cambrex Corporation
- Catalent
- Emergent BioSolutions
- Fujifilm Diosynth
- Hovione
- Jubilant Pharmova
- Laurus Labs
- Lonza Group
- Recipharm AB
- Samsung Biologics
- Siegfried Holding AG
- Syngene International Ltd.
- Thermo Fisher Scientific
- WuXi AppTec
- WuXi Biologics
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 162 |
| Published | April 2025 |
| Forecast Period | 2024 - 2030 |
| Estimated Market Value ( USD | $ 11.3 Billion |
| Forecasted Market Value ( USD | $ 15.8 Billion |
| Compound Annual Growth Rate | 5.8% |
| Regions Covered | Global |
